GlassScriptPhysician profile
Lindsey G Mclear
NPI 1366935298
$3,981.01
in general payments reported to CMS, 2019-2025
45 companies · $811 in 2025
The $811 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $336 · 2022: $1,280 · 2023: $743 · 2024: $811 · 2025: $811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,975 · Education: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,975.01 |
| Education | $390.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $391.21 | 2021-2025 | |
| Amgen INC. | $262.61 | 2022-2023 | Kyprolis, Lumakras |
| Novartis Pharmaceuticals Corporation | $219.30 | 2021-2025 | |
| Janssen Biotech, INC. | $192.73 | 2021-2025 | Rybrevant |
| Takeda Pharmaceuticals U.S.A., INC. | $186.21 | 2021-2024 | Alunbrig, Fruzaqla |
| Merck Sharp & Dohme LLC | $184.82 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $184.61 | 2022-2025 | Datroway, Enhertu |
| Regeneron Healthcare Solutions, INC. | $170.64 | 2022-2025 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $165.34 | 2022-2025 | Imfinzi, Calquence |
| Seagen INC. | $146.95 | 2022-2025 | Padcev |
| Emd Serono, INC. | $146.12 | 2022-2025 | Bavencio |
| Incyte Corporation | $130.60 | 2024-2025 | Monjuvi, Pemazyre, Jakafi |
| Ultragenyx Pharmaceutical INC. | $125.00 | 2022 | |
| Celgene Corporation | $119.12 | 2022-2025 | Reblozyl, Abecma |
| E.R. Squibb & Sons, L.L.C. | $118.58 | 2022-2025 | Opdivo, Opdualag |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $113.23 | 2024 | Onivyde |
| Eisai INC. | $108.34 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $98.00 | 2023 | |
| Glaxosmithkline, LLC. | $95.59 | 2023-2025 | Jemperli, Zejula |
| Myriad Genetic Laboratories, INC. | $68.45 | 2023 | Myrisk |
| Genmab U.S., INC. | $62.81 | 2023 | Tivdak |
| Blueprint Medicines Corporation | $56.87 | 2023-2024 | Ayvakit |
| Pharmacyclics LLC, An Abbvie Company | $53.56 | 2022-2023 | Imbruvica |
| Gilead Sciences, INC. | $49.33 | 2022-2024 | |
| Aveo Pharmaceuticals, INC. | $47.63 | 2022-2024 | |
| Abbvie INC. | $44.43 | 2021-2025 | |
| Array Biopharma INC | $43.61 | 2022-2024 | Mektovi, Braftovi, Xalkori |
| Adc Therapeutics America, INC. | $43.44 | 2022-2023 | |
| Lilly USA, LLC | $39.29 | 2022-2023 | Jaypirca, Retevmo, Verzenio |
| Karyopharm Therapeutics INC. | $35.14 | 2022-2025 | Xpovio |
| Pharmacosmos Therapeutics INC. | $31.57 | 2025 | Monoferric |
| Servier Pharmaceuticals LLC | $21.41 | 2024 | |
| Genzyme Corporation | $20.90 | 2024 | |
| Exelixis INC. | $20.89 | 2024 | Cabometyx |
| Novo Nordisk INC | $19.97 | 2022 | |
| Beigene USA, INC. | $18.21 | 2025 | Brukinsa |
| Astellas Pharma US INC | $18.17 | 2025 | Padcev |
| Foundation Medicine, INC. | $18.12 | 2023 | |
| Dendreon Pharmaceuticals LLC | $17.89 | 2023 | Provenge |
| Novocure INC. | $17.83 | 2025 | Optune Gio |
| Agios Pharmaceuticals, INC. | $17.24 | 2025 | Pyrukynd |
| Sobi, INC | $14.79 | 2024 | |
| Genentech USA, INC. | $13.66 | 2022 | |
| Myovant Sciences INC. | $13.50 | 2022 | |
| Epizyme, INC. | $13.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Mclear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.